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Results:  The study population consisted of 206 patients treated 
with surgery and 136 patients treated with RT. Median follow up 
was 6.6 years. Patients in the surgical cohort were younger, with 
mean age: 48.9 versus 60.7 years, p < 0.001, and had larger 
tumours, with mean maximum dimension: 25.7 +/- 10.3 mm 
versus 20.3 +/- 6.6 mm, p < 0.001. After all VS treatments, the 
population’s PFS was 92.8 +/- 1.5% at five years and 83.7% +/- 
2.9% at 10 years. The population’s SH preservation at last follow 
up was 34.2%. SAEs occurred in 4.7% of patients. In the 
radiotherapy cohort of 136 patients, 17% had previous surgery 
(four complete resection, five planned subtotal resection and 14 
unplanned partial resection). Sixty-seven percent had single-
fraction stereotactic radiosurgery and 33% had fractionated 
stereotactic radiotherapy. Seven percent had progressive disease 
requiring salvage surgery. Eighteen percent had FND (HB Grade 
2 or more) at presentation. No patients had improvement in FND 
after RT and 17% had new or worsened FND after treatment. SAEs 
were: hydrocephalus requiring ventriculoperitoneal shunt 1.5%, 
radionecrosis 0.7%, hospitalization for steroid myopathy 0.7%, 
and death from complications of disease 0.7%. In the surgical 
cohort of 206 patients, 8% had previous treatment (eight 
radiation, nine surgery). The most common surgical approaches 
were retrosigmoid (89%) and translabyrinthine (6%). Two percent 
had planned post-op RT and 12% had disease progression 
requiring salvage: 19 RT, three surgery, two unknown. Twelve 
percent had FND at presentation. FND improved in 4.4% and 
worsened in 12.6% after surgery. SAEs were: increased 
intracranial pressure requiring external ventricular drain 2.9%, 
dural fistula requiring lumbar drain 1.5%, evacuation of 
hematoma 1.0%, and perioperative death 0.5%. 
Conclusions:  Multidisciplinary management of VS provides 
excellent disease control at a population level with hearing 
preservation in a minority of patients and a low-risk of serious 
adverse events. 
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Purpose: Conventional imaging methods, such as computed 
tomography (CT) and magnetic resonance imaging (MRI) are not 
as effective as magnetic resonance spectroscopy (MRS) in 
diagnosing, grading, and evaluating high-grade glioma (HGG) 
tumour response to treatment1. MRS uniquely determines 
whether tumour is viable or contains metabolic activity following 
post-operative radiotherapy (RT). This study’s preliminary data 
was published2, and has currently become the largest 
prospective trial to investigate the correlation between changes 
in MRS spectra in HGG patients before, during, and after post-
operative RT with overall survival (OS). 
Methods and Materials: Forty-four patients with histologically 
confirmed HGG prospectively completed surgery and RT to 6000 
cGy. MRS was performed prior to starting RT, during week 4 of 
RT, and at two months post-RT. Metabolite ratios of: 1) choline 
/ creatine; 2) NAA/creatine; and 3) choline/NAA were calculated 
from MRS spectra at each time point. Normalized metabolite 
ratios, defined as Tumour metabolite/Normal contralateral brain 
metabolite, were evaluated for differences in OS from baseline 
to post-RT. Kaplan-Meier curves of OS were analyzed for 
statistical significance by the log-rank method, and paired groups 
of metabolite ratios examining changes over time were 
compared using the paired t-test, with a significance value of α 
= 0.05. 
Results: After a median follow up of 21.0 months, mean 
normalized choline significantly decreased from baseline to two 
months post-RT (1.98 versus 1.35, p = 0.019). Patients with < 60% 
decrease in normalized choline from baseline to two months 
post-RT had a significantly better median OS (34.98 versus 10.49 
months, p = 0.049). Moreover, patients with any increase in 
normalized choline from baseline to week 4 of RT had 
significantly better median OS after completing RT (39.19 versus 
16.09 months, p = 0.037). 
Conclusions: This study is the largest prospective trial to 
demonstrate that changes in normalized choline from baseline to 
two months post-RT are highly predictive for OS. These 
prognostic MRS changes further strengthen the clinical use of 
advanced imaging techniques to improve the diagnostic and 
grading effectiveness of imaging, to noninvasively sample the 
molecular features of gliomas, to evaluate local tumour response 
to radiotherapy, and to optimize individualized treatments for 
patients with HGG. 
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Purpose: Rectal toxicity can be a significant consequence of 
prostate radiation therapy, and a number of different dosimetric 
parameters have been used with the intention of decreasing 
rectal toxicity. This has led to a wide array of retrospective trials 
wherein different definitions of the rectum led to variation in 
DVH (dose volume histogram) data. Compounding this, many 
dose escalation studies have been done in the last decade after 
a close relationship between local control and radiation dose was 
found. This resulted in a variety of DVH recommendations 
without clear consensus in the literature.  
Methods and Materials: As part of a quality assurance task, 
random data on 50 consecutive prostate cancer patients treated 
at our institution with rapid arc protocol was analyzed. Defined 
constraints were studied and evaluated: if they fulfilled organ at 
risk (OAR) limitations as per institutional protocol, or if some 
OAR constraints were too stringent. This included rectal V40 Gy 
< 55%, which has not been quoted in recent RTOG trials.  
Results: Rectal data analysis highlighted that V75 Gy < 15%, V70 
Gy < 20% and V60 Gy < 35% were achieved in all patients. V65 Gy 
< 25% and V50 Gy < 50% were achieved in 98% of the patients. 
V40 Gy < 55% was achieved only in 54% of the patients. Bladder 
constraints including V80 Gy < 15%, V75 Gy < 25% and V70 Gy < 
35% were achieved in all patients. However, V65 Gy < 50% and 
V40 Gy < 70 % were achieved in 96% of the patients. Mean dose 
of < 50Gy for Penile bulb was achieved in only 74% of patients. 
Femoral head tolerance (V53 Gy < 5%) was met in all patients. 
Bowel DVH of V45 Gy < 195 cc was met for most of the patients. 
However, contouring differed between radiation oncologists for 
the bowel. 
Conclusions: Rectal dose constraints to decrease the probability 
of rectal toxicity have been based on a number of studies. 
Although these constraints are not achievable in a significant 
number of patients, stringent parameters have been put forward 
with the intention of decreasing rectal toxicity. Confounding 
variables make interpretation of data with these stringent 
parameters difficult. Recent RTOG studies have not included 
stringent parameters of V40Gy < 55%. More studies need to be 
done to determine if this stringent parameter can be omitted 
altogether. 
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